Stanley Hazen, MD

• Chair, Gordon Research Conference on Oxygen Radicals
• Jeffrey M Hoeg Arteriosclerosis, Thrombosis and Vascular Biology Award for Basic Science and Clinical Research
• Election, Association of American Physicians (AAP)
• Election, Fellow of American Heart Association Scientific Council for Arteriosclerosis
• Election, American Society for Clinical Investigation

• Howard Hughes Medical Institute Research Fellowship for Physicians Award, 1995-1997 
• AAP, ASCI, and AFMR Certificate of Achievement Award, 1997 
• Marilyn Hansen American Thoracic Society Award, 1997
• Junior Faculty Award, American Federation of Medical Research, 1999 
• Gill Heart Institute Physician Scientist Award, University of Kentucky, Lexington Ky., 2001 
• Election, American Society for Clinical Investigation, 2003 
• John J. Ferchill Award for Innovation, Cleveland Clinic, 2004 
• Nomination, Howard Hughes Medical Institute Investigator Award, 2004 
• Vice-Chair, Gordon Research Conference on Oxygen Radicals, 2006 
•  Jeffrey M Hoeg Arteriosclerosis, Thrombosis and Vascular, 2007 

Cleveland Clinic physicians and scientists collaborate with industry to advance medical breakthroughs. These partnerships help commercialize discoveries for public benefit while maintaining scientific integrity. To ensure transparency and minimize potential bias, Cleveland Clinic reviews these relationships and publicly discloses when physicians/scientists receive significant compensation for consulting, serve in fiduciary roles, receive royalties, or hold equity interests related to their work. We manage potential conflicts through approval processes, annual reporting, and targeted management plans.

As of 2025-01-08, Dr. Hazen has reported the financial relationships with the companies listed below.

Royalty Payments. Dr. Hazen receives or has the right to receive royalty payments for inventions or discoveries commercialized through the companies shown below:

• Zehna Therapeutics, LLC
• Procter & Gamble
• Cleveland HeartLab, Inc. (a wholly-owned subsidiary of Quest Diagnostics, Incorporated)

Right to Future Distribution of Cleveland Clinic Financial Interest. Dr. Hazen may receive future financial benefits from the Cleveland Clinic for inventions or discoveries commercialized through the companies shown below:

• Zehna Therapeutics, LLC

Consulting and/or Speaking. Dr. Hazen receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Zehna Therapeutics, LLC

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.